Core Viewpoint - Noveris Health Sciences Inc. is currently facing a trading halt imposed by the British Columbia Securities Commission due to unusual trading activity and has clarified misinformation regarding its FDA registration status [1][2]. Group 1: Trading Halt - The British Columbia Securities Commission issued an order halting all trading in Noveris Health Sciences Inc.'s securities until April 16, 2026, due to unexplained fluctuations in trading volume and market price [1]. - The company intends to cooperate fully with the BCSC to meet any conditions necessary for the resumption of trading [3]. Group 2: Clarification on Misinformation - Noveris Health Sciences Inc. has not authorized or been involved in the creation or distribution of an article by John Michaels, which inaccurately claimed that the company is FDA-registered [2]. - The company confirms it has no registrations with the FDA and is not pursuing any applications for registration for its products at this time [2]. Group 3: Company Overview - Noveris Health Sciences Inc. is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD [4]. - The company's strategy combines advanced technology with a robust infrastructure for drug discovery and development, aiming to create breakthrough treatment solutions [4]. - Noveris is also focusing on the next generation of psychedelic medicine, developing innovative compounds with significant therapeutic potential through clinical trials [4].